[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354627-105":59,"doc-detail-354627-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-validation-of-four-point-of-care-high-risk-hpv-assays-including-two-reduced-valency-assays-for-cervical-cancer-screening-in-low-resource-settings","Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings","","Persistent infection with high-risk human papillomavirus (HR-HPV) is a necessary cause of cervical cancer, accounting for about 95% of cases attributable to eight carcinogenic types (16/18/31/33/35/45/52/58). In low-resource settings, India-developed HR-HPV assays—including reduced-valency tests—were clinically evaluated. Clinical accuracy and reproducibility were assessed in a blinded analysis of 1159 ESTAMPA samples (97 CIN2+) using reference assays (Cobas-4800, Allplex-HPV-HR). Truenat-HR-HPV-Plus met IARC criteria and showed robust sensitivity and specificity, with high repeatability, while HPV-Q and PathoDetect-HPV-14 did not.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-validation-of-four-point-of-care-high-risk-hpv-assays-including-two-reduced-valency-assays-for-cervical-cancer-screening-in-low-resource-settings/354627/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-validation-of-four-point-of-care-high-risk-hpv-assays-including-two-reduced-valency-assays-for-cervical-cancer-screening-in-low-resource-settings/354627.png","ImageObject",300,407,{"name":92,"@type":93},"OmBimo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What condition does the study focus on and what role does HR-HPV play?","Question",{"text":112,"@type":113},"The study focuses on cervical cancer screening, where persistent HR-HPV infection is identified as the necessary cause of cervical cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which assays were evaluated and how was clinical performance measured?",{"text":117,"@type":113},"Four point-of-care HR-HPV assays were evaluated—PathoDetect-HPV-14, HPV-Q, Truenat-HRHPV-Plus, and PathoDetect-HPV-7. Performance was compared in a blinded manner against reference tests (Cobas-4800 and Allplex-HPV-HR), assessing sensitivity, specificity, agreement, and repeatability.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key results for Truenat-HRHPV-Plus in CIN2+ screening?",{"text":121,"@type":113},"Truenat-HRHPV-Plus demonstrated sensitivity of 80.4% and specificity of 91.5% for CIN2+. It met IARC validation criteria and showed non-inferior performance versus the reference Allplex-HPV-HR-8.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354627,1790160044,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","International Journal of Cancer  \nRESEARCH ARTICLE  OPEN ACCESS   \nCancer Therapy and Prevention  \nClinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings  \nNeerja Bhatla1 | MaryLuz Rol2  | Seema Singhal1 | Showket Hussain3 | Anushree Patil4 | Pranay Tanwar1 | Shalini Singh3 | Vikrant M. Bhor4 | Kiran Munne4  | Richa Vashishtha5 | Shachi Vashist1 | Eric Lucas2 | Richard Muwonge2 |  \nArianis Tatiana Ramírez2 | Anju Singh1 | Vikas Khan1 | Jyoti Rani3 | Nasera Firdausi3 | Sandeep Sisodiya3 |  \nRutuja Wakchaure4 | María Alejandra Picconi6 | Alejandro Calderón7 | Margo Bell8 | Annemie De Smet8 | Alex Vorsters8 | Gary M. Clifford2  | Madhavi Chandra5 | Jitendra Kumar5 | Partha Basu2   \n1All India Institute of Medical Sciences, New Delhi, India | 2Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France | 3ICMR-National Institute of Cancer Prevention and Research, Noida, India | 4ICMR-National Institute for Research on Women's Health (ICMR-NIRWoH), Formerly ICMR-NIRRCH, Mumbai, India | 5Biotechnology Industry Research Assistance Council, Department of Biotechnology, New Delhi, India | 6Instituto Nacional de Enfermedades Infecciosas – ANLIS Malbrán, Buenos Aires, Argentina | 7Caja Costarricense de Seguro Social, San José, Costa Rica | 8Centre for the Evaluation of Vaccination (CEV), Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium  \nCorrespondence: MaryLuz Rol ([rolm@iarc.who.int](rolm@iarc.who.int)) | Showket Hussain (showket.hussain@gov.in)  \nReceived: 6 January 2026 | Revised: 15 April 2026 | Accepted: 21 April 2026  \nKeywords: cervical cancer screening | clinical validation | high-risk HPV assays | low-resource settings  \nABSTRACT  \nPersistent infection with high-risk human papillomavirus (HR-HPV) is the necessary cause of cervical cancer, with approximately 95% of cases attributable to eight most carcinogenic HPV types (16/18/31/33/35/45/52/58). Several HPV assays have recently been developed in India for use in cervical cancer screening, including reduced-valency tests targeting seven/eight oncogenic HPV types. We evaluated the clinical accuracy and reproducibility of four such assays: PathoDetect-HPV-14, HPV-Q (14 types), Truenat-HRHPV-Plus (8 types), and PathoDetect-HPV-7 (7 types). Using the VALGENT framework, 1159 cervical samples from the ESTAMPA study conducted in Argentina and Costa Rica were analysed with the new assays. The samples included 97 cases ofCIN2+ (19 CIN2, 72 CIN3, and 6 cancers). Assay performance was compared in a blinded manner with established reference tests (Cobas-4800 and Allplex-HPV-HR) and reduced-valency comparators. Sensitivity, specificity, agreement, and repeatability were assessed. TruenatHR-HPV-Plus demonstrated a sensitivity of 80.4%(95% CI: 71.1–87.8) and specificity of 91.5%(95% CI: 89.5–93.2) for CIN2+. It met IARC validation criteria and showed non-inferior performance to Allplex-HPV-HR-8, with relative sensitivity of 1.03 (95% CI: 0.96–1.09) for CIN2+ and 1.00 (95% CI: 0.96–1.04) for CIN3+, and relative specificity of 0.99 (95% CI: 0.97–1.00) and 0.98 (95% CI: 0.97–1.00), respectively. Repeatability was 93.3%(κ = 0.79). PathoDetect-HPV-7 showed lower sensitivity (68.1%) with specificity of 89.0%. HPV-Q and PathoDetect-HPV-14 did not meet validation criteria. This study represents the first formal validation of reducedvalency HPV assays and demonstrates that Truenat-HR-HPV-Plus provides robust clinical performance with higher specificity than 14-valent assays, supporting its potential to improve screening efficiency and reduce unnecessary referrals.  \n\n| Abbreviations: CI, confidence interval; Ct, cycle threshold; HR-HPV, high-risk human papillomavirus; LMICs, low-and middle-income countries; NNF, number of women needing follow-up; NNS, number of women need","cbCaifsoXjb0T8k0","https://ap.wps.com/l/cbCaifsoXjb0T8k0","pdf",613156,11,"English","# Abstract\n# What's New?\n# Introduction","[{\"question\":\"What condition does the study focus on and what role does HR-HPV play?\",\"answer\":\"The study focuses on cervical cancer screening, where persistent HR-HPV infection is identified as the necessary cause of cervical cancer.\"},{\"question\":\"Which assays were evaluated and how was clinical performance measured?\",\"answer\":\"Four point-of-care HR-HPV assays were evaluated—PathoDetect-HPV-14, HPV-Q, Truenat-HRHPV-Plus, and PathoDetect-HPV-7. Performance was compared in a blinded manner against reference tests (Cobas-4800 and Allplex-HPV-HR), assessing sensitivity, specificity, agreement, and repeatability.\"},{\"question\":\"What were the key results for Truenat-HRHPV-Plus in CIN2+ screening?\",\"answer\":\"Truenat-HRHPV-Plus demonstrated sensitivity of 80.4% and specificity of 91.5% for CIN2+. It met IARC validation criteria and showed non-inferior performance versus the reference Allplex-HPV-HR-8.\"}]","Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings | PDF",1790112645,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d2f5281362157692e1f971807302c8c.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1df448d35419b91c72fc11d2cba80e77.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6abe43e8986a35617a2152a90a84f3c2.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15ee7b7c8980d00155421b46172db15e.webp",980,1287]